490 related articles for article (PubMed ID: 29668124)
21. Candida glabrata and Candida krusei fungemia after high-risk allogeneic marrow transplantation: no adverse effect of low-dose fluconazole prophylaxis on incidence and outcome.
Safdar A; van Rhee F; Henslee-Downey JP; Singhal S; Mehta J
Bone Marrow Transplant; 2001 Nov; 28(9):873-8. PubMed ID: 11781648
[TBL] [Abstract][Full Text] [Related]
22. Epidemiology, management, and outcome of invasive fungal disease in patients undergoing hematopoietic stem cell transplantation in China: a multicenter prospective observational study.
Sun Y; Meng F; Han M; Zhang X; Yu L; Huang H; Wu D; Ren H; Wang C; Shen Z; Ji Y; Huang X
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1117-26. PubMed ID: 25840339
[TBL] [Abstract][Full Text] [Related]
23. [The clinical characteristic and risk factors for the incidence of invasive fungal infection in patients following allogeneic hematopoietic stem cell transplantation].
Zhang Y; Liu C; Liu QF; Sun J; Fan ZP; Xu D; Jiang QL
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(40):2814-7. PubMed ID: 20137659
[TBL] [Abstract][Full Text] [Related]
24. Outcome of non-mold effective anti-fungal prophylaxis in patients at high-risk for invasive fungal infections after allogenic stem cell transplantation.
Christen D; Sohlbach K; Metzelder SK; Wollmer E; Hoeffkes HG; Naumann R; Burchardt A; Rummel M; Trenker C; Dohse M; Mack E; Klameth A; Mann C; Kostrewa P; Brendel C; Wündisch T; Neubauer A; Wilhelm C; Burchert A
Leuk Lymphoma; 2019 Aug; 60(8):2056-2061. PubMed ID: 30644334
[TBL] [Abstract][Full Text] [Related]
25. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial.
Winston DJ; Maziarz RT; Chandrasekar PH; Lazarus HM; Goldman M; Blumer JL; Leitz GJ; Territo MC
Ann Intern Med; 2003 May; 138(9):705-13. PubMed ID: 12729424
[TBL] [Abstract][Full Text] [Related]
26. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
27. Clinical experience with posaconazole prophylaxis--a retrospective analysis in a haematological unit.
Hahn J; Stifel F; Reichle A; Holler E; Andreesen R
Mycoses; 2011 Jan; 54 Suppl 1():12-6. PubMed ID: 21126267
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation.
Linke C; Ehlert K; Ahlmann M; Fröhlich B; Mohring D; Burkhardt B; Rössig C; Groll AH
Mycoses; 2020 Feb; 63(2):172-180. PubMed ID: 31661569
[TBL] [Abstract][Full Text] [Related]
29. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
30. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
[TBL] [Abstract][Full Text] [Related]
31. A targeted fungal prophylaxis protocol with static dosed fluconazole significantly reduces invasive fungal infection after liver transplantation.
Jorgenson MR; Descourouez JL; Marka NA; Leverson GE; Smith JA; Andes DR; Fernandez LA; Foley DP
Transpl Infect Dis; 2019 Oct; 21(5):e13156. PubMed ID: 31390109
[TBL] [Abstract][Full Text] [Related]
32. Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions.
El Cheikh J; Otrock ZK; Qannus AA; Kharfan-Dabaja MA; Bazarbachi A
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):304-10. PubMed ID: 26923326
[TBL] [Abstract][Full Text] [Related]
33. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
34. MTX or mycophenolate mofetil with CsA as GVHD prophylaxis after reduced-intensity conditioning PBSCT from HLA-identical siblings.
Piñana JL; Valcárcel D; Fernández-Avilés F; Martino R; Rovira M; Barba P; Martínez C; Brunet S; Sureda A; Carreras E; Sierra J
Bone Marrow Transplant; 2010 Sep; 45(9):1449-56. PubMed ID: 20140024
[TBL] [Abstract][Full Text] [Related]
35. The Role of Fluconazole Prophylaxis Regimen and the Regimes Chosen by the Patient’s Risk of Fungal Infection in Reducing the Infection Rate after Bone Marrow Transplantation.
Pourghasemian M; Mehdizadeh M; Hajfathali A; Habibzadeh A; Hosseini MH
Asian Pac J Cancer Prev; 2018 Jun; 19(6):1543-1546. PubMed ID: 29936729
[TBL] [Abstract][Full Text] [Related]
36. Calcineurin inhibitor--free graft-versus-host disease prophylaxis with post-transplantation cyclophosphamide and brief-course sirolimus following reduced-intensity peripheral blood stem cell transplantation.
Solomon SR; Sanacore M; Zhang X; Brown S; Holland K; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1828-34. PubMed ID: 25064745
[TBL] [Abstract][Full Text] [Related]
37. Prospective trial of mycophenolate mofetil-cyclosporine A prophylaxis for acute GVHD after G-CSF stimulated allogeneic bone marrow transplantation with HLA-identical sibling donors in patients with severe aplastic anemia and hematological malignancies.
Ostronoff F; Ostronoff M; Souto-Maior AP; Domingues M; Sucupira A; Manso DA; de Lima AK; Monteiro PG; Florêncio R; Calixto R
Clin Transplant; 2009; 23(1):33-8. PubMed ID: 18727660
[TBL] [Abstract][Full Text] [Related]
38. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
39. [Outcome of allogeneic hematopoietic stem cell transplantation from HLA-matched sibling donor for 41 cases of severe aplastic anemia].
Chen X; Wei JL; Huang Y; He Y; Yang DL; Jiang EL; Ma QL; Zhou LK; Lin XT; Shen YY; Feng SZ; Han MZ
Zhonghua Xue Ye Xue Za Zhi; 2012 Aug; 33(8):610-4. PubMed ID: 23134851
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT.
El-Cheikh J; Venton G; Crocchiolo R; Fürst S; Faucher C; Granata A; Oudin C; Coso D; Bouabdallah R; Vey N; Duran S; Fougereau E; Berger P; Chabannon C; Blaise D
Bone Marrow Transplant; 2013 Nov; 48(11):1472-7. PubMed ID: 23749104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
